Sysmex Corporation ADR (OTCMKTS:SSMXY) Sees Significant Decline in Short Interest

Sysmex Corporation ADR (OTCMKTS:SSMXY) saw a large decrease in short interest in the month of September. As of September 30th, there was short interest totaling 135,510 shares, a decrease of 44.9% from the September 15th total of 245,925 shares. Based on an average daily volume of 334,412 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.0% of the company’s shares are sold short.

Sysmex Stock Down 2.1%

SSMXY opened at $11.53 on Thursday. Sysmex has a 12 month low of $8.01 and a 12 month high of $12.90. The business has a 50-day moving average of $11.89 and a two-hundred day moving average of $10.03. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.40 and a quick ratio of 2.53. The stock has a market capitalization of $7.01 billion, a price-to-earnings ratio of 27.45 and a beta of 1.18.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings data on Friday, August 7th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.02. Sysmex had a net margin of 7.62% and a return on equity of 8.01%. The business had revenue of $825.85 million for the quarter, compared to analyst estimates of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. On average, research analysts expect that Sysmex will post 0.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Sysmex from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 18th. Two research analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

Sysmex Company Profile

Sysmex Corporation is a Japan-based healthcare technology company that develops, manufactures and distributes in vitro diagnostic products and laboratory solutions. The company is best known for its automated hematology analyzers, which are used to examine blood cells, along with related reagents, software and support services.

Its product portfolio also includes systems for hemostasis, urinalysis, clinical chemistry and immunochemistry, as well as laboratory automation and information-management solutions.